摘要
目的观察长春瑞滨(NVB)、异环磷酰胺(IFO)、顺铂(PDD)三药联合(NIP)治疗晚期非小细胞肺癌的疗效和毒性.方法共收治ⅢB～Ⅳ期非小细胞肺癌98例,其中鳞癌51例,腺癌42例,大细胞癌5例.ⅢB期59例,Ⅳ期39例.初治71例,复治27例.方案:NVB 25 mg/m2静滴,第1,8天;IFO 1.5 g/m2,静滴,第1～3天;PDD 30 mg/m2,静滴,第1～3天.4周为一周期.结果 CR 1例,PR 44例,NC 45例,PD 8例,总有效率(CR+PR)为45.9%.中位缓解期8个月,中位生存期11个月,1年生存率为48.0%.骨髓抑制为剂量限制性毒性,其中Ⅲ～Ⅳ度占40.8%.结论 NIP方案是治疗晚期非小细胞肺癌有效且安全的方案.
Objective To evaluate the efficacy and toxicity of combination chemotherapy of navelbine （NVB）,ifosfamide（IFO） and cisplatin（PDD） in the treatment of advanced non-small cell lung cancer（NSCLC）. Methods Ninety-eight patients with advanced NSCLC were treated. Histological distribution included 51 squamous cell carcinomas,42 adenocarcinomas and 5 large cell carcinomas. Stage distribution was 59 stage ⅢB and 39 stage Ⅳ. Seventy-one patients had no prior chemotherapy and 27 were previously treated. The chemotherapy regimen consisted of NVB 25 mg/m^2 on days 1 and 8, IFO 1.5 g/m^2 and PDD 30 mg/m^2 on days 1-3 every 4 weeks. Results The overall response rate was 45.9% with 1 complete responses（1.0%） and 44 partial responses （44.9%） .The median time to progression was 8 months. The median survival 11 months. One-year survival was 48.0%. The dose limiting toxicity was leukopenia with grades Ⅲ - Ⅳ in 40.8%.Conclusion NIP is active and safe in advanced NSCLC. It should be warrant for further study.
出处
《中国肿瘤临床与康复》
2005年第4期338-339,共2页
Chinese Journal of Clinical Oncology and Rehabilitation
